In this article, we will look at the 14 Best Long-Term Penny Stocks to Buy Right Now.
On August 29, Ed Yardeni, President of Yardeni Research, appeared on CNBC’s ‘Closing Bell’ to talk about the latest news impacting markets, the possible factors that might inspire the next market surge, and more.
He stated that the market is feeling like a slow-motion melt-up, continually going higher and higher. The earnings story has been great, according to him, with Q1 earnings coming in better than expected.
The same thing happened in Q2, which Yardeni considers “remarkable” considering the uncertainty and turmoil from tariffs. Earnings have moved past these headwinds, and the US market appears to be back on its winning track.
READ ALSO: 13 High Growth Low PE Stocks to Invest In Now and 15 Strong Buy Stocks Under $5 to Buy Now.
He added that the market loves Fed puts, so if we get a Fed put and the economy doesn’t really need it, that would result in further melt-up.
The overall outlook is that we are in a bull market right now, with a tremendous amount of buying power and lots of buying on the dips.
With these trends in view, let’s look at the best long-term penny stocks to buy right now.
Our Methodology
We used Finviz to compile an initial list of top stocks with a 5-year revenue growth above 10% and a stock price under $5. We then selected the top 14 stocks with the highest number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on August 29.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
14 Best Long-Term Penny Stocks to Buy Right Now
14. ImmunityBio, Inc. (NASDAQ:IBRX)
Stock Price: $2.33
5-Year Revenue Growth Rate: 46.27%
Number of Hedge Fund Holders: 14
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best long-term penny stocks to buy right now. On August 26, ImmunityBio, Inc. (NASDAQ:IBRX) announced the early findings of the first five recurrent glioblastoma patients that were treated with its investigational immune-boosting regimen, including ANKTIVA, in this pilot study.
The company reported that all five patients attained 100% disease control with the regimen that “combines ANKTIVA, an IL-15 agonist being studied for its ability to enhance natural killer (NK) cell activity, NK cell therapy (PD-L1 t-haNK), and Optune Gio Tumor Treating Fields.”
The study showed that the ANKTIVA treatment raised absolute lymphocyte count (ALC) in all five patients who had experienced lymphopenia after standard of care radiation and chemotherapy.
Management stated that the results were highly encouraging, with “5 out of 5 (100%) disease control in 2nd line recurrent glioblastoma receiving a chemotherapy-free immunotherapy with Optune immune-stimulating device.”
Based on these initial findings, ImmunityBio, Inc. (NASDAQ:IBRX) is starting a “randomized trial targeting second-line GBM patients who have recurring disease following standard of care.”
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.
13. Silvercorp Metals, Inc. (NYSE:SVM)
Stock Price: $4.64
5-Year Revenue Growth Rate: 14.01%
Number of Hedge Fund Holders: 15
Silvercorp Metals, Inc. (NYSE:SVM) is one of the best long-term penny stocks to buy right now. Silvercorp Metals, Inc. (NYSE:SVM) reported its fiscal Q1 2026 results on August 7, producing approximately 1.8 million ounces of silver, 2,050 oz of gold, or around 2.0 million ounces of silver equivalent, 15.7 million pounds of lead, and 5.2 million lb of zinc.
The company also announced that it sold around 1.8 million oz of silver, 1,951 oz of gold, 15.2 million lb of lead, and 5.2 million lb of zinc, with the revenue reaching $81.3 million.
On August 7, Raymond James analyst Craig Stanley raised the firm’s price target on Silvercorp Metals, Inc. (NYSE:SVM) to C$8 from C$7.50, keeping an Outperform rating on the shares.
Similarly, Roth MKM analyst Joseph Reagor maintained a Buy rating on Silvercorp Metals, Inc. (NYSE:SVM) on August 11 and set a price target of $6.50.
The stock’s median price target of $4.64 implies an upside of 32.26% from current levels.
Silvercorp Metals (NYSE:SVM) is a Canadian mining company that produces gold, silver, lead, and zinc. It operates several silver-lead-zinc mines in China, including the Ying Mining District in Henan Province and the GC silver-lead-zinc mine in Guangdong Province.
While the company’s producing mines are in China, its development and exploration projects are in Mexico and China.
12. Olaplex Holdings, Inc. (NASDAQ:OLPX)
Stock Price: $1.45
5-Year Revenue Growth Rate: 23.32%
Number of Hedge Fund Holders: 16
Olaplex Holdings, Inc. (NASDAQ:OLPX) is one of the best long-term penny stocks to buy right now. In a report released on August 25, Susan Anderson from Canaccord Genuity upgraded Olaplex Holdings, Inc. (NASDAQ:OLPX) to a Buy with a price target of $2.00.
The analyst based the positive rating on the company’s market positioning and growth potential, stating that Olaplex Holdings, Inc. (NASDAQ:OLPX) underwent a brand revitalization and is now in a position to leverage its prestige status in the beauty industry to attain renewed growth.
Anderson added that Olaplex Holdings, Inc. (NASDAQ:OLPX) is experiencing stabilization in both margins and sales after a period marked with fluctuations, and the recent quarters are exhibiting positive growth for the first time in several quarters.
Olaplex Holdings, Inc. (NASDAQ:OLPX) is a technology-driven beauty company focusing on hair health. Its portfolio comprises complementary products specialized to improve hair health.
These products have three uses: protection, maintenance, and treatment. The company’s products are offered through specialty retail, professional, and direct-to-consumer (DTC) channels.
11. Borr Drilling Limited (NYSE:BORR)
Stock Price: $2.96
5-Year Revenue Growth Rate: 20.85%
Number of Hedge Fund Holders: 17
Borr Drilling Limited (NYSE:BORR) is one of the best long-term penny stocks to buy right now. On August 27, Borr Drilling Limited (NYSE:BORR) announced new contract commitments for two of its premium jack-up rigs and offered an additional fleet update.
The company reported that Prospector 1 in the North Sea attained separate binding Letters of Award from Dana Petroleum and ONE-Dyas in the Netherlands.
The Dana Petroleum commitment is for one well that has an expected duration of 30 days, set to commence in November 2025. The ONE-Dyas commitment, in contrast, encompasses a period of three wells and has an expected duration of 210 days. It is anticipated to commence in December 2025, in direct continuation of the previous contract.
Borr Drilling Limited (NYSE:BORR) added that the ONE-Dyas award includes options that may extend the work by an extra 210 days.
Management also announced that in West Africa, the Natt secured a contract with New Age in Congo, adding that the “firm scope of one well has an anticipated duration of 60 days scheduled to commence in November 2025.”
The new commitments include a combined duration of 300 days, representing more than $43 million in “contract revenue backlog, excluding options, mobilization, and demobilization compensation.”
Borr Drilling Limited (NYSE:BORR) also announced that the previously announced LOA for the “Odin” in Mexico has been converted into a contract, with the rig commencing operations under the contract.
Borr Drilling Limited (NYSE:BORR) provides offshore drilling services to the oil and gas industry. It operates through the Dayrate and Integrated Well Services (IWS) segments. The Dayrate segment provides rig charters and ancillary services, while the IWS segment offers integrated well services through Opex and Akal.
10. TELUS International (Cda) Inc. (NYSE:TIXT)
Stock Price: $3.83
5-Year Revenue Growth Rate: 21.11%
Number of Hedge Fund Holders: 20
TELUS International (Cda) Inc. (NYSE:TIXT) is one of the best long-term penny stocks to buy right now. On August 25, ShiftMed announced a strategic partnership with TELUS International (Cda) Inc. (NYSE:TIXT) aimed at enabling health systems to improve margins by combining TELUS International (Cda) Inc.’s (NYSE:TIXT) specialized digital solutions and expertise in custom integrations with ShiftMed’s AI-powered workforce platform.
Management stated that the partnership would address the “unique challenges of complex healthcare organizations” and “streamline staffing operations.”
TELUS International (Cda) Inc. (NYSE:TIXT) provides IT services and multilingual customer services. Its operations are divided into the following geographical segments: Asia Pacific, Europe, Central America, and North America. The Asia Pacific segment includes China, India, Japan, the Philippines, Singapore, and South Korea.
9. Riskified Ltd. (NYSE:RSKD)
Stock Price: $4.78
5-Year Revenue Growth Rate: 20.20%
Number of Hedge Fund Holders: 21
Riskified Ltd. (NYSE:RSKD) is one of the best long-term penny stocks to buy right now. On August 20, JPMorgan analyst Reginald Smith downgraded Riskified Ltd. (NYSE:RSKD) to Underweight from Neutral without assigning a price target.
The analyst told investors in a research note that Riskified Ltd.’s (NYSE:RSKD) volume growth and revenue have trailed the broader e-commerce group, attributed to weakness within travel and the luxury sector.
The firm is now “increasingly skeptical” about Riskified Ltd.’s (NYSE:RSKD) ability to scale into its 2026 adjusted EBITDA margin targets of 15%-20%, creating an overhang on the shares.
Riskified Ltd. (NYSE:RSKD) is involved in fraud prevention solutions, empowering businesses by making e-commerce safe, frictionless, and accessible. The company operates an electronic commerce risk management platform that enables online merchants to develop trusted relationships with its customers.
8. Plug Power Inc. (NASDAQ:PLUG)
Stock Price: $1.63
5-Year Revenue Growth Rate: 20.98%
Number of Hedge Fund Holders: 23
Plug Power Inc. (NASDAQ:PLUG) is one of the best long-term penny stocks to buy right now. On August 14, Wells Fargo analyst Michael Blum raised the firm’s price target on the stock to $1.50 from $1 while keeping an Equal Weight rating on the shares.
The firm cited a shift forward in the base year of its valuation model to 2026 and a slightly higher EBITDA forecast, stating that it is remaining on the sidelines due to the low visibility surrounding positive profit margins.
In a report released on August 12, David Arcaro from Morgan Stanley maintained a Sell rating on Plug Power Inc. (NASDAQ:PLUG), setting a price target of $0.75.
In another report released on the same day, BMO Capital also maintained a Sell rating on Plug Power Inc. (NASDAQ:PLUG) with a $1.00 price target.
The stock’s median price target of $1.63 implies an upside of 8.90% from current levels.
Plug Power Inc. (NASDAQ:PLUG) provides alternative energy technology focusing on the development, design, manufacturing, and commercialization of hydrogen and fuel cell systems that are primarily employed for the material handling and stationary power markets.
7. MannKind Corporation (NASDAQ:MNKD)
Stock Price: $4.49
5-Year Revenue Growth Rate: 37.26%
Number of Hedge Fund Holders: 26
MannKind Corporation (NASDAQ:MNKD) is one of the best long-term penny stocks to buy right now. On August 25, H.C. Wainwright reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), setting a $9 price target.
The firm told investors in a research note that it considers the company’s scPharmaceuticals acquisition positively, adding that it expects MannKind Corporation’s (NASDAQ:MNKD) shares to benefit from a more diversified revenue base.
It added that MannKind Corporation (NASDAQ:MNKD) paid a “very reasonable” price for the acquisition.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases.
The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.
6. Lucid Group, Inc. (NASDAQ:LCID)
Stock Price: $2.07
5-Year Revenue Growth Rate: 181.26%
Number of Hedge Fund Holders: 27
Lucid Group, Inc. (NASDAQ:LCID) is one of the best long-term penny stocks to buy right now. In a report released on August 21, Tom Narayan from RBC Capital maintained a Hold rating on Lucid Group, Inc. (NASDAQ:LCID), setting a price target of $2.00.
Lucid Group, Inc. (NASDAQ:LCID) reported its fiscal Q2 2025 results on August 5, announcing that it produced 3,863 vehicles in the quarter and delivered 3,309 vehicles, up 38.2% compared to fiscal Q2 2024.
Revenue for the quarter reached $259.4 million, with a GAAP diluted net loss per share of $0.28.
Lucid Group, Inc. (NASDAQ:LCID) ended fiscal Q2 2025 with around $4.86 billion in total liquidity and revised its production outlook for 2025 to 18,000 – 20,000 vehicles from prior guidance of 20,000 vehicles.
Lucid Group, Inc. (NASDAQ:LCID) is a manufacturer of electric vehicles. The company develops, designs, and builds energy storage systems for EVs and provides automakers with the battery pack system necessary to power plug-in, hybrid, and electric vehicles.
5. Taboola.com Ltd. (NASDAQ:TBLA)
Stock Price: $3.35
5-Year Revenue Growth Rate: 10.06%
Number of Hedge Fund Holders: 28
Taboola.com Ltd. (NASDAQ:TBLA) is one of the best long-term penny stocks to buy right now. Taboola.com Ltd. (NASDAQ:TBLA) announced its fiscal Q2 2025 results on August 6, reporting revenues of $465.5 million, up 8.7%. The growth was attributed to an 8.5% growth in Scaled Advertisers, supported by a 1.8% increase in Average Revenue per Scaled Advertiser.
The company also reported a gross profit of $135.6 million, reflecting an increase of 18.2%.
On August 7, B. Riley analyst Zach Cummins raised the firm’s price target on Taboola.com Ltd. (NASDAQ:TBLA) to $4.50 from $4, keeping a Buy rating on the shares after the Q2 beat.
In another report released on August 7, John Blackledge from TD Cowen also reiterated a Buy rating on Taboola.com Ltd. (NASDAQ:TBLA) with a price target of $4.00.
Similarly, Needham also assigned a Buy rating to the stock on the same day, setting a $4.50 price target.
Its median price target of $3.35 implies an upside of 26.87% from current levels.
Taboola.com Ltd. (NASDAQ:TBLA) is a technology company that powers recommendations across the Open Web, partnering with devices, websites, and mobile apps to recommend advertisements and editorial content on the Open Web. This occurs outside the closed ecosystems of “walled gardens” like Amazon, Facebook, and Google.
4. GoodRx Holdings, Inc. (NASDAQ:GDRX)
Stock Price: $4.36
5-Year Revenue Growth Rate: 11.14%
Number of Hedge Fund Holders: 28
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best long-term penny stocks to buy right now. On August 19, Leerink Partners analyst Michael Cherny reiterated the Buy rating on GoodRx Holdings, Inc. (NASDAQ:GDRX), keeping the associated price target at $6.00.
The analyst based the rating on the company’s strategic advancements, stating he considers the recent agreement with Novo Nordisk to offer discounted prices for Wegovy and Ozempic to be a significant achievement for GoodRx Holdings, Inc.’s (NASDAQ:GDRX) manufacturer solutions segment.
The collaboration points towards the potential of GoodRx Holdings, Inc.’s (NASDAQ:GDRX) platform, connecting more than 70,000 retail pharmacies in the US with 5.5 million monthly active users and serving as a notable channel for direct-to-consumer pharmaceutical advertising.
GoodRx Holdings, Inc. (NASDAQ:GDRX) offers a consumer-focused digital healthcare platform that provides free consumer access to convenient medical provider consultations through telehealth, reduced prices for brand and generic medications, and extensive healthcare research and information.
3. Blend Labs, Inc. (NYSE:BLND)
Stock Price: $3.54
5-Year Revenue Growth Rate: 26.17%
Number of Hedge Fund Holders: 31
Blend Labs, Inc. (NYSE:BLND) is one of the best long-term penny stocks to buy right now. In a report released on August 21, Joseph Vafi from Canaccord Genuity maintained a Buy rating on Blend Labs, Inc. (NYSE:BLND), setting a price target of $5.25.
Blend Labs, Inc. (NYSE:BLND) reported its fiscal Q2 2025 results on August 7, with total revenue for the quarter reaching $31.5 million, up by $2.8 million, or 10%, compared to the same period last year.
Management added that total revenue comprised Software platform revenue of $29.4 million and Professional services revenue of $2.1 million.
Blend Labs, Inc. (NYSE:BLND) further reported that the total GAAP gross profit margin was 74% in fiscal Q2 2025, while the non-GAAP gross profit margin was 76%, both up compared to 71% on both a GAAP and non-GAAP basis in fiscal Q2 2024.
Blend Labs, Inc. (NYSE:BLND) provides a cloud-based software platform for financial services firms developed to power the end-to-end consumer journey for banking products. The company’s operations are divided into the Blend Platform and Title365 segments.
2. Clarivate Plc (NYSE:CLVT)
Stock Price: $4.31
5-Year Revenue Growth Rate: 19.83%
Number of Hedge Fund Holders: 33
Clarivate Plc (NYSE:CLVT) is one of the best long-term penny stocks to buy right now. On August 27, Clarivate Plc (NYSE:CLVT) announced that it signed agreements for the provision of its leading academic research and intellectual property (IP) solutions to China Petrochemical Corporation (Sinopec Group).
The collaboration aims at bolstering the “research and development goals of Mainland China’s largest oil and petrochemical products supplier”, ultimately delivering impactful innovation and research.
Clarivate Plc (NYSE:CLVT) provides global information, workflow solutions, and analytics. The company operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H).
1. Geron Corporation (NASDAQ:GERN)
Stock Price: $1.43
5-Year Revenue Growth Rate: 233.77%
Number of Hedge Fund Holders: 37
Geron Corporation (NASDAQ:GERN) is one of the best long-term penny stocks to buy right now. Geron Corporation (NASDAQ:GERN) reported its fiscal Q2 2025 results on August 6, announcing $49.0 million in RYTELO net product revenue in the quarter.
Management also reported that the Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and is anticipated to be fully enrolled by year-end.
On August 15, Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Geron Corporation (NASDAQ:GERN), keeping the associated price target the same at $3.00.
In another report released on August 7, Barclays also maintained a Buy rating on Geron Corporation (NASDAQ:GERN) with a $4.00 price target.
The stock’s median price target of $1.43 implies an upside of 179.72% from current levels.
Geron Corporation (NASDAQ:GERN) is a biotechnology company that develops Imetelstat, a telomerase inhibitor in hematologic myeloid malignancies. It focuses on oncology-focused therapeutic products.
While we acknowledge the potential of GERN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GERN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
